Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine

IntroductionOnabotulinum toxin A (OnabotA) cyclic treatment is approved for the prophylactic treatment of chronic migraine (CM), a highly disabling disorder. Although treatment response varies among patients, current guidelines suggest to stop treatment after cycle 2 if no response is achieved. This...

Full description

Bibliographic Details
Main Authors: Paola Sarchielli, Michele Romoli, Ilenia Corbelli, Laura Bernetti, Angela Verzina, Elona Brahimi, Paolo Eusebi, Stefano Caproni, Paolo Calabresi
Format: Article
Language:English
Published: Frontiers Media S.A. 2017-12-01
Series:Frontiers in Neurology
Subjects:
chronic migraine
onabotulinum toxin A
botox
migraine
migraine treatment
Online Access:http://journal.frontiersin.org/article/10.3389/fneur.2017.00655/full

Internet

http://journal.frontiersin.org/article/10.3389/fneur.2017.00655/full

Similar Items